Liensinine, a new inhibitor of autophagy and/or mitophagy, could enhance the sensitivity of breast cancer cells to chemotherapy via mitochondrial fission mediated by DNM1L (Zhou et al., 2015). This evidence concerns the gene DNM1L and breast cancer.